Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
Not Applicable
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Other: Blood draw
- Registration Number
- NCT00566423
- Lead Sponsor
- Northwell Health
- Brief Summary
The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.
- Detailed Description
As above
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
- Confirmed diagnosis of PAH, based on currently accepted gold standard for Right Heart Catheterization.
- Patients with mean artery pressure of greater that 25 mm Hg at rest or 30mm Hg during exercise with pulmonary capillary wedge pressure less than 18mm Hg on right heart catheterization.
Exclusion Criteria
- Significant left heart disease or renal insufficiency (serum creatinine > 1.5 mg%).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Blood draw Patients with Pulmonary Arterial Hypertension
- Primary Outcome Measures
Name Time Method Assess the correlation of plasma/arterial BNP and MIF levels pre/post with the 6 Minute walk test distance and echocardiographic parameters as surrogate markers of severity of PAH. 2 year
- Secondary Outcome Measures
Name Time Method To determine if changes in plasma/arterial MIF levels pre/post 6MW test are due to MIF released from the lungs 2 year
Trial Locations
- Locations (1)
North Shore-Long Island Health System
🇺🇸New Hyde Park, New York, United States